A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19

Table 3

Secondary outcomes.

	Baricitinib + dexamethasone + remdesivir n = 81	Dexamethasone + remdesivir n = 110	Odds ratio	value	95% CI
Requirement of mechanical ventilation			0.66	0.26	0.31–1.36
Not requiring mechanical ventilation (%)	14 (17.3)	28 (25.5)
Mean (days)	10.9	10.7
Median (days)	9.5	9.5
Length of stay (days)			t − 0.39	0.74
Mean (95% CI)	13.74 (11.44–16.04)	13.31 (11.89–14.73)
Median	11	12
High-flow oxygen (days)			t − 1.39	0.16
Mean (95% CI)	8.95 (6.91–10.99)	7.28 (5.91–8.65)
Median	7	5